Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

BACKGROUND: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective supportive therapy in the management of side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacquinot, Quentin, Meneveau, Nathalie, Falcoz, Antoine, Bouhaddi, Malika, Roux, Pauline, Degano, Bruno, Chatot, Marion, Curtit, Elsa, Mansi, Laura, Paillard, Marie-Justine, Bazan, Fernando, Chaigneau, Loïc, Dobi, Erion, Meynard, Guillaume, Vernerey, Dewi, Pivot, Xavier, Mougin, Fabienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537598/
https://www.ncbi.nlm.nih.gov/pubmed/36211552
http://dx.doi.org/10.3389/fcvm.2022.1000846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537598/
https://www.ncbi.nlm.nih.gov/pubmed/36211552
http://dx.doi.org/10.3389/fcvm.2022.1000846

Ejemplares similares